Some users believe John Harper's hair regrowth claims using dermarolling, coffee, and oils are misleading, while others defend his methods. The conversation highlights skepticism about alternative treatments and emphasizes finasteride, dutasteride, and minoxidil as proven solutions for hair loss.
Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.
The user is using minoxidil and finasteride to treat hair loss and is concerned about shedding and potential aggressive hair loss. They noticed some regrowth in trichoscopy pictures but are unsure about real-life changes.
Experimenting with the effects of creatine and finasteride on DHT levels, as well as a discussion regarding the potential link between creatine supplementation and hair loss.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
The user has been on finasteride for 1.5 years with good results but avoids minoxidil due to pet safety concerns. They're considering alternatives like Redensyl and natural remedies like rosemary oil and stinging nettle tincture for hair loss.
The conversation discusses using ecklonia cava as a natural alternative to finasteride for hair loss. Users share their experiences and opinions on its effectiveness.
The conversation discusses the potential of topical cetirizine (Zyrtec) for hair growth in comparison to minoxidil, noting cetirizine's ability to reduce prostaglandin D2, which inhibits hair growth. Users share mixed experiences with cetirizine for allergies and scalp health, and there's a mention of the risk of dementia with long-term antihistamine use.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
The user is experiencing significant hair shedding after four months of using topical finasteride and minoxidil, questioning if it's a normal shedding phase or if the treatment isn't working. They are considering switching to oral treatments and have increased their finasteride concentration, while also using keto and caffeine shampoos.
User started DUT 3 times a week, topical minoxidil/tretinoin at night, and topical stemoxydine/alfatradiol mix with tretinoin in the morning for hair loss. They experienced significant progress and no side effects, crediting a YouTuber for encouragement.
A user wants to add cetirizine tablets to their minoxidil bottle and asks how many 10mg tablets to crush for a 100ml bottle. They seek advice on the correct dosage.
The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
The user has been taking 1mg of finasteride daily for a year, maintaining hair density without regrowth. They are considering oral minoxidil for regrowth, avoiding topical minoxidil due to its toxicity to cats, despite concerns about heart side effects.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.
Cecred hair drops, containing keratin and biotin, are questioned for their effectiveness compared to proven treatments like minoxidil. Users express skepticism, suggesting deceptive marketing and the possibility of undisclosed use of other treatments like finasteride.
The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.
There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
A user asked if they can crush caffeine and melatonin tablets to add to their minoxidil solution. Another user sarcastically suggested adding rat poison.
Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.
Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.
The conversation discusses hair loss treatment with finasteride, which has shown positive results for the user over 1.5 years. Concerns about using minoxidil due to its toxicity to pets, especially cats, are also highlighted.
The user is considering using 0.5 mg dutasteride once every 5 or 7 days due to side effects from finasteride and is also looking into topical liposomal dutasteride and pyrilutamide to stop hair loss. The goal is to stop hair loss, not regrow hair.